Plumbagin as a mutli-target drug in treatment of cancer: A review

---

Review Article

Author Details : Prashant N. Amale, Shilpa A. Deshpande

Volume : 2, Issue : 1, Year : 2017

Article Page : 30-37

Suggest article by email

Get Permission

---

Abstract

Cancer is the fastest growing disease and leading cause of death in the world. Several drugs are available for the treatment of cancer with their merits and demerits, but not a single molecule is available which claims to cure cancer completely. Plumbagin (PL) is a napthoquinone derivative which is obtained as secondary metabolite from plumbago plant family, plumbaginaceae. Plambago plants are the flowering plants naturally occurring in Asia, Plumbago zeylanica specially found in India. Previously it was known as “chitraka” (in Ayurveda) whose root extracts were used for the treatment of dyspepsias, piles and diarrhoea. PL found to arrest the cell proliferation, metastasis and growth in various in-vitro and in-vivo studies Several researchers showed that PL modulates cytokines like interleukins, nuclear factor kappa B (NF-kB), tumour necrosis factor alpha (TNF-?), reactive oxygen species (ROS), phosphatidyl-inositol 3 kinase (PI3K) & p38 mitogen-activated protein kinase (MAPK), DNA degradation, jun n-terminal kinase (JNK), protien kinase-C (PKc), mechanistic target of rapamycin (mTOR) and signal transducers and activators of transcription (STAT) which are key player in the growth and development of normal cell at molecular level. PL found to arrest rapidly dividing cells, due to these features and activities, PL can be used in treatment of different kinds of cancers. This article provides an overview on the anti-cancer mechanism and speciality of a single agent PL, as a multi-target molecule obtained from plumbaginous plant in treatment of various types of cancer.

Keywords: Plumbagin, Multi-target, Anticancer, Apoptosis.

How to cite : Amale P N, Deshpande S A, Plumbagin as a mutli-target drug in treatment of cancer: A review. Indian J Clin Anat Physiol 2017;2(1):30-37

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.